loading
前日終値:
$16.92
開ける:
$17.24
24時間の取引高:
433.12K
Relative Volume:
1.03
時価総額:
$481.34M
収益:
$157.75M
当期純損益:
$-29.73M
株価収益率:
-15.32
EPS:
-1.16
ネットキャッシュフロー:
$-21.00M
1週間 パフォーマンス:
-1.55%
1か月 パフォーマンス:
+8.29%
6か月 パフォーマンス:
-18.78%
1年 パフォーマンス:
-49.63%
1日の値動き範囲:
Value
$16.63
$17.86
1週間の範囲:
Value
$16.54
$19.25
52週間の値動き範囲:
Value
$14.30
$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name
名前
Arcturus Therapeutics Holdings Inc
Name
セクター
Healthcare (1169)
Name
電話
(858) 900-2660
Name
住所
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
職員
180
Name
Twitter
@ArcturusRx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
ARCT's Discussions on Twitter

ARCT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ARCT
Arcturus Therapeutics Holdings Inc
17.77 481.34M 157.75M -29.73M -21.00M -1.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-28 開始されました BTIG Research Buy
2024-08-12 開始されました Leerink Partners Outperform
2023-12-13 開始されました Canaccord Genuity Buy
2023-07-24 開始されました William Blair Outperform
2023-05-11 アップグレード H.C. Wainwright Neutral → Buy
2022-11-14 再開されました Wells Fargo Overweight
2022-11-10 ダウングレード Robert W. Baird Neutral → Underperform
2022-11-03 アップグレード Citigroup Neutral → Buy
2022-11-02 アップグレード Barclays Underweight → Equal Weight
2022-08-10 ダウングレード Raymond James Mkt Perform → Underperform
2022-07-19 再開されました Cantor Fitzgerald Overweight
2022-05-11 アップグレード Robert W. Baird Underperform → Neutral
2022-04-21 ダウングレード Citigroup Buy → Neutral
2022-01-31 アップグレード Raymond James Underperform → Mkt Perform
2021-08-12 ダウングレード Raymond James Mkt Perform → Underperform
2021-08-11 ダウングレード Goldman Neutral → Sell
2021-08-10 ダウングレード Robert W. Baird Neutral → Underperform
2021-07-02 開始されました Cantor Fitzgerald Overweight
2021-06-25 再開されました Goldman Neutral
2021-06-21 ダウングレード Barclays Equal Weight → Underweight
2021-06-04 再開されました Robert W. Baird Neutral
2021-02-17 ダウングレード B. Riley Securities Neutral → Sell
2021-01-19 ダウングレード B. Riley Securities Buy → Neutral
2021-01-15 ダウングレード B. Riley Securities Buy → Neutral
2021-01-07 開始されました Wells Fargo Overweight
2020-12-29 ダウングレード Barclays Overweight → Equal Weight
2020-12-29 ダウングレード H.C. Wainwright Buy → Neutral
2020-12-29 ダウングレード Raymond James Outperform → Mkt Perform
2020-12-29 ダウングレード Robert W. Baird Outperform → Neutral
2020-12-23 ダウングレード ROTH Capital Buy → Sell
2020-12-08 繰り返されました B. Riley Securities Buy
2020-12-07 繰り返されました B. Riley Securities Buy
2020-10-26 開始されました Barclays Overweight
2020-10-06 開始されました Citigroup Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-30 再開されました ROTH Capital Buy
2020-07-16 開始されました Raymond James Outperform
2020-07-13 開始されました B. Riley FBR Buy
2020-06-09 ダウングレード WBB Securities Buy → Hold
2020-02-11 開始されました Robert W. Baird Outperform
2020-02-07 開始されました Guggenheim Buy
2020-02-06 開始されました Guggenheim Buy
2019-04-05 開始されました H.C. Wainwright Buy
2018-09-20 アップグレード WBB Securities Buy → Strong Buy
2018-01-22 開始されました Chardan Capital Markets Buy
すべてを表示

Arcturus Therapeutics Holdings Inc (ARCT) 最新ニュース

pulisher
Feb 20, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 9.9% in January - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

Empire Life Investments Inc. Purchases 128,771 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Feb 19, 2025
pulisher
Feb 18, 2025

HC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat

Feb 18, 2025
pulisher
Feb 16, 2025

The week in pharma: action, reaction and insight – week to February 14 - The Pharma Letter

Feb 16, 2025
pulisher
Feb 16, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from Analysts - Defense World

Feb 16, 2025
pulisher
Feb 16, 2025

Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $65.00 - MarketBeat

Feb 16, 2025
pulisher
Feb 16, 2025

Sumitomo Mitsui Trust Group Inc. Has $35.04 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

EC approves CSL and Arcturus’ Kostaive - The Pharma Letter

Feb 15, 2025
pulisher
Feb 15, 2025

CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine - Marketscreener.com

Feb 15, 2025
pulisher
Feb 14, 2025

Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views - Benzinga

Feb 14, 2025
pulisher
Feb 14, 2025

ARCTArcturus Therape Latest Stock News & Market Updates - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

Arcturus Therapeutics Says EU Commission Approves COVID-19 Vaccine Kostaive - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics - Nasdaq

Feb 14, 2025
pulisher
Feb 14, 2025

Revolutionary COVID Vaccine Breakthrough: New Technology Shows Year-Long Immunity in EU Approval - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - The Malaysian Reserve

Feb 14, 2025
pulisher
Feb 13, 2025

Selling Arcturus Therapeutics Holdings Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St

Feb 13, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Has $203,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Feb 08, 2025
pulisher
Feb 05, 2025

Arcturus Therapeutics names Moncef Slaoui as Chair Designate - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

State Street Corp Reduces Holdings in Arcturus Therapeutics Holdings Inc - GuruFocus.com

Feb 05, 2025
pulisher
Feb 05, 2025

Arcturus Therapeutics names Moncef Slaoui as Chair Designate By Investing.com - Investing.com Australia

Feb 05, 2025
pulisher
Feb 05, 2025

Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Increases By 8.6% - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

Global mRNA Vaccines and Therapeutics Market is expected - openPR

Feb 04, 2025
pulisher
Feb 04, 2025

Arcturus Therapeutics Appoints Moncef Slaoui Chair Designate -February 04, 2025 at 10:40 am EST - Marketscreener.com

Feb 04, 2025
pulisher
Feb 04, 2025

Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire

Feb 04, 2025
pulisher
Jan 31, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research - MarketBeat

Jan 31, 2025
pulisher
Jan 31, 2025

Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - StockTitan

Jan 31, 2025
pulisher
Jan 30, 2025

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - BioSpace

Jan 30, 2025
pulisher
Jan 30, 2025

BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

ARCT (Arcturus Therapeutics Holdings) Cash-to-Debt : 8.06 (As of Sep. 2024) - GuruFocus.com

Jan 29, 2025
pulisher
Jan 28, 2025

BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation - Nasdaq

Jan 28, 2025
pulisher
Jan 28, 2025

Arcturus: Downgrading As mRNA Promise Meets Market Reality (NASDAQ:ARCT) - Seeking Alpha

Jan 28, 2025
pulisher
Jan 28, 2025

Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews - Benzinga

Jan 28, 2025
pulisher
Jan 28, 2025

BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target -January 28, 2025 at 07:27 am EST - Marketscreener.com

Jan 28, 2025
pulisher
Jan 27, 2025

Arcturus Therapeutics to Present at the Investor Summit on December 17th in Philadelphia. - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 25, 2025

Leerink Partnrs Has Positive Outlook of ARCT FY2024 Earnings - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

What is Leerink Partnrs' Forecast for ARCT FY2024 Earnings? - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Cantor Fitzgerald Forecasts ARCT FY2025 Earnings - Defense World

Jan 24, 2025
pulisher
Jan 24, 2025

Q3 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Q3 Earnings Forecast for ARCT Issued By Leerink Partnrs - MarketBeat

Jan 23, 2025
pulisher
Jan 22, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - Defense World

Jan 22, 2025
pulisher
Jan 21, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World

Jan 21, 2025

Arcturus Therapeutics Holdings Inc (ARCT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):